Lung Cancer Treatment in China: What the Panel Changes, What a City Package Doesn't
Lung cancer in China is a molecular-plan problem. IARC GLOBOCAN 2024: 1,175,915 new cases and 743,336 deaths. EGFR mutations are more common in East Asia (about 30-40% vs 10-15% in Western cohorts). Send histology and EGFR/ALK/ROS1/PD-L1. About 24 hours. No obligation to book.
Average reply: 24 hoursNo obligation to book
1.18 million casesIARC 2024 China
EGFR first30-40% in Asia
No lung packagepanel or no shortlist
Quick answer
Lung cancer in China is a molecular-plan problem, not a city package. IARC GLOBOCAN 2024: 1,175,915 new cases and 743,336 deaths — first in both. EGFR mutations are more common in East Asia (~30-40% vs ~10-15% in Western cohorts). NCCN NSCLC v1.2026 maps first-line EGFR options to osimertinib plus chemo and amivantamab plus lazertinib as preferred. CAR-T is not standard lung-cancer care. Send histology and EGFR/ALK/ROS1/PD-L1. About 24 hours. No obligation to book.
Lung: what the file must split
NSCLC vs SCLC
Different disease. A mixed ‘lung package’ is not a plan.
Minimum panel
EGFR, ALK, ROS1, PD-L1. Broader NGS (KRAS, MET, RET, BRAF) when possible.
Not standard here
CAR-T for lung = trial only. Proton = selected geometry, not metastatic spray.
| Question | Usual comparison | Cost note |
|---|---|---|
| Molecular NSCLC / IO | CAMS/NCC, Fudan, SYSUCC, PKU Cancer, Tianjin | Drugs dominate — no single band |
| Selected proton / re-irradiation | SPHIC, Ruijin — imaging first | Course band ~USD 20-35k if accepted |
| ‘Lung CAR-T’ ad | Treat as trial until named | Do not use blood-cancer CAR-T prices |
What actually changes the plan
📋
Molecular profile first
NSCLC vs SCLC, then EGFR/ALK/ROS1/KRAS/MET/RET/PD-L1. No panel, no serious shortlist.
🏥
Thoracic department, not a brand
CAMS/NCC, Fudan, SYSUCC, Tianjin, PKU Cancer. SPHIC only if the geometry needs a beam.
✈️
Drug and stay drivers
Targeted/IO lines and inpatient days move the bill. We will not quote a lung package from a screenshot.
What this page helps you decide
✅
NSCLC and SCLC split
We do not mix small-cell protocols into an adenocarcinoma brochure.
💬
CAR-T labelled as trial-only here
Lung is not the blood-cancer CAR-T page. We say no when an ad says otherwise.
🌍
Stage-4 goals in writing
Control and symptoms when cure is not the endpoint.
Evidence table
IARC lung burden, NCCN v1.2026 EGFR maps, East-Asian EGFR prevalence.
| Source | What it says | Relevance to patients |
|---|---|---|
| IARC GLOBOCAN China (2024) | 1,175,915 cases; 743,336 deaths | Volume is real. Not a ranking of your file. |
| NCCN NSCLC (v1.2026) | Full panel; preferred first-line EGFR regimens updated | No panel, no honest shortlist. |
| MARIPOSA Asia reporting (2025) | EGFR ~30-40% Asia vs ~10-15% West | Why an Asian lung file without EGFR is incomplete. |
| CSCO NSCLC (2025) | 3rd-generation EGFR-TKI preferred class | Domestic TKIs exist; they still need the mutation. |
Who this page is for
NSCLC with a driver mutation
Need a centre that will treat the molecular report, not a generic ablation package.
SCLC or biomarker-negative NSCLC
Need an honest systemic plan and stage-4 goals, not a sold 'China cure'.
Families comparing targeted-drug quotes
Need the same line compared across hospitals, including what the drug costs extra.
What you can actually book
Public thoracic volume: CAMS/NCC, PKU Cancer, FUSCC, Shanghai Chest, SYSUCC, Guangdong Lung Cancer Institute. SPHIC only for a defined beam. Related: cancer hub, proton.
What moves the cost
Lung file review
No charge to start
NSCLC/SCLC split • Biomarker gaps • Centre shortlist • Cost-driver note
Coordinated trip
Quoted after records
Hospital matching • Drug/stay drivers • Visa • Interpreter
These are routing steps, not a hospital package SKU. Published procedure examples stay in the evidence/cost sections only when a source exists. Hospital, drugs, stay, interpreter and travel are quoted separately after records.
What happens next
01
Send histology and NGS
Plus staging imaging and prior systemic lines. Missing EGFR/ALK/PD-L1 restarts the clock.
02
Match department and line
Targeted, IO, chemo, surgery, selected radiation/proton — each labelled.
03
Travel after a centre will see you
Invitation, visa, interpreter. No exploratory flight for a missing molecular report.
Request a preliminary case review
Tell us the basics of your case. When you submit, WhatsApp will open with the information you entered so you can review it before sending. This is a preliminary routing request, not a diagnosis, treatment acceptance, trial enrollment, visa decision, or medical advice.
Frequently asked questions
How much is lung cancer treatment in China?
It depends on the driver. EGFR TKIs, immunotherapy, surgery and selected proton are different invoices. We itemise after the panel. There is no generic lung package.
Why does EGFR matter more in China?
East-Asian NSCLC has a higher EGFR-mutation share, commonly cited around 30-40% versus 10-15% in Western cohorts. A file without EGFR is incomplete.
Is CAR-T used for lung cancer?
Not as standard of care. Solid-tumour cell programmes need a trial ID.
Which hospitals?
CAMS/NCC, PKU Cancer, FUSCC, Shanghai Chest, SYSUCC, Guangdong Lung Cancer Institute. SPHIC only for a defined beam.
NSCLC or SCLC — does it matter?
Yes. They do not share a protocol.
What records should I send?
Histology, NGS or at least EGFR/ALK/ROS1/PD-L1, staging CT/PET, smoking and performance status, prior lines.
Is proton default for lung?
No.
Do you promise a response rate?
No. Average reply about 24 hours. No obligation to book.
Do I pay before you read the file?
No. Payment required before a file review is a red flag. Average reply about 24 hours. No obligation to book.
How fast do you reply?
About 24 hours. We label the file as labelled care, trial, or marketing. No obligation to book.
Red flags in offers
A “China lung package” or proton as default. Immunotherapy sold on top of an unused TKI. Fuda as the lung hospital. None of that replaces the panel.
Quote without EGFR/ALK/PD-L1.
CAR-T for NSCLC with no trial ID.
One package for SCLC and NSCLC.
Pay before slides and CT are read.
Sources
IARC GLOBOCAN 2024 China fact sheet.
NCCN NSCLC Version 1.2026.
CSCO 2025 NSCLC updates (3rd-gen EGFR-TKI preferred).
MARIPOSA Asia-cohort EGFR prevalence reporting.
Freshness label on this page: 2026-08-15
Medical note
A treating oncologist should review imaging and pathology before you travel. This page is matching information, not a treatment recommendation.